Jazz Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jazz Pharmaceuticals plc
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Rise in state-legalized marijuana helped pushed FDA to recommend more lenient regulation of the substance, easing pathway to prescription drug approval, but those same state markets may pose a challenge for commercialization of an Rx botanical if DEA follows through on rescheduling.
The drug maker plans to move the drug into Phase III development for NT1, though it appears to have missed on NT2. But a lack of key toxicities may bode well for the orexin agonist class too.
The UK biotech has teamed up again with Jazz, banking a $10m upfront fee that will help towards advancing its wholly owned ROCK inhibitor program for fibrosis indications.
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.